Go offline with the Player FM app!
Decoding Federal Dollars: Grant Engine CEO Sam Tetlow on the Evolving Biohealth Funding Map
Manage episode 487151840 series 1551347
In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what’s changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.
Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC’s Kenan-Flagler Business School.
Editing and post-production work for this episode was provided by The Podcast Consultant.
178 episodes
Manage episode 487151840 series 1551347
In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what’s changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.
Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC’s Kenan-Flagler Business School.
Editing and post-production work for this episode was provided by The Podcast Consultant.
178 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.